---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-031820"
form_type: "8-K/A"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2023-06-28T23:59:59+00:00"
generated_at: "2026-06-13T15:32:47.761871+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Roivant corrects Immunovant TED Phase 3 data timeline to H1 2025; reports Q4 revenue $27.4M, loss $0.05/share

## Summary
- Corrected timeline for Immunovant's Phase 3 TED trials: topline data expected in H1 2025 (previously misstated).
- Q4 product revenue from VTAMA $13.7M; fiscal year VTAMA revenue $28.0M; over 170,000 prescriptions since launch.
- Cash and equivalents $1.7B as of March 31, 2023; cash runway into H2 2025.
- RVT-3101 Phase 2b UC data showed improved efficacy from week 14 to week 56; Phase 2 Crohn's study initiated.
- Net loss attributable to Roivant $33.6M ($0.05 per share) for Q4 vs $270.1M loss year ago; loss from continuing ops $175.4M.

## SEC filing metadata
- accession: 0001140361-23-031820
- form_type: 8-K/A
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2023-06-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036123031820/0001140361-23-031820-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036123031820/brhc20055123_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-031820
- JSON: https://secwatch.observer/filing/0001140361-23-031820.json
- Plain text: https://secwatch.observer/filing/0001140361-23-031820.txt

## Key facts
- Earnings Releases
  Roivant Sciences Ltd. reported financial results for fourth quarter and fiscal year ended March 31, 2023.
  - Period: fourth quarter and fiscal year ended March 31, 2023
  - Result: reported results
  source text: Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2023, and provided an update on the business.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000114036123031820/0001140361-23-031820-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.